Drug Profile
Tocilizumab - Chugai Pharmaceutical/Roche
Alternative Names: Actemra; ACTPen; Anti-IL-6 receptor antibody - Chugai; Anti-interleukin-6 receptor antibody - Chugai; Atlizumab; HPM-1; MRA; MRA - Chugai; MRA-SC; R-1569; RG-1569; rhPM-1; RO4877533; RoActemraLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical; Osaka University
- Developer Assistance Publique Hopitaux de Paris; Biomedical Advanced Research and Development Authority; Charite - Universitatsmedizin Berlin; Chugai Pharmaceutical; Hospital for Special Surgery; JW Pharmaceutical; Roche; University Hospital Inselspital; University Hospital Tubingen; University of Bern; University of Pittsburgh
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections; COVID-19 pneumonia; Drug hypersensitivity; Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis; Systemic scleroderma
- Registered Adult-onset Still's disease; Vasculitis
- Phase III Osteoarthritis
- Phase II Amyotrophic lateral sclerosis; Dermatomyositis; Familial Mediterranean fever; Polymyalgia rheumatica; Polymyositis; Pulmonary arterial hypertension; Schnitzler syndrome
- Phase I/II Urogenital cancer
- Phase I Pancreatic cancer
- No development reported Chronic lymphocytic leukaemia
- Discontinued Ankylosing spondylitis; Crohn's disease; Multiple myeloma; Systemic lupus erythematosus
Most Recent Events
- 13 Sep 2023 Regulatory submission withdrawn for Systemic scleroderma in European Union (SC)
- 09 May 2023 Registered for COVID-19 pneumonia in Taiwan (IV) before May 2023 (Chugai Pharmaceuticals pipeline, May 2023)
- 23 Feb 2023 Tocilizumab is still in phase III trials for Systemic scleroderma in Belgium, Bulgaria, France, Germany, Greece, Denmark, Croatia, Netherlands, Lithuania, Hungary, Italy, Ireland, Romania, Switzerland, Spain, Portugal, Poland